Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 1 of 31 PageID #: 1600
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`C.A. No. 1:19-cv-00638-CFC
`
`
`
`GENENTECH, INC. and CITY OF HOPE,
`
`
`
`Plaintiffs and Counterclaim
`Defendants,
`
` v.
`
`
`PFIZER INC.
`
`
`
`PFIZER INC.
`
`
`
`Defendant and Counterclaim
`Plaintiff.
`
`
`Counterclaim Plaintiff,
`
`
`v.
`
`HOFFMAN-LA ROCHE, INC.,
`
`
`
`Counterclaim Defendant.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`STIPULATED PROTECTIVE ORDER
`
`WHEREAS, Plaintiffs Genentech, Inc. and City of Hope, Defendant Pfizer Inc., and
`
`Counterclaim Defendant Hoffman La-Roche (collectively the “Parties”) expect discovery
`
`requests made in this Litigation to encompass certain information which may constitute trade
`
`secrets and/or other confidential research, development, or commercial information within the
`
`meaning of Federal Rule of Civil Procedure 26(c)(1)(G) for which special protection from public
`
`disclosure and from use for any purpose other than in this Litigation is warranted, the Parties, by
`
`and through their respective Outside Counsel, HEREBY STIPULATE to the entry of this
`
`
`ME1 30989659v.1
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 2 of 31 PageID #: 1601
`
`
`
`Protective Order regarding discovery in District of Delaware Civil Litigation No. 19-638,
`
`including any appeals therefrom (herein “Litigation”).
`
`DEFINITIONS
`
`1.
`
`“Affiliate” means any Third Party that directly or indirectly through one or more
`
`intermediaries, controls, or is controlled by, or is under common control with, a Party to this
`
`Litigation.
`
`2.
`
`“CONFIDENTIAL” means information that constitutes, contains, reveals, or
`
`reflects trade secrets or other confidential research, development, business, or commercial
`
`information within the meaning of Fed. R. Civ. P. 26(c)(1)(G), including but not limited to:
`
`scientific and technical information; product information; financial, budgeting and/or accounting
`
`information; information about existing and potential customers; marketing and other business
`
`strategies, decisions, or negotiations; personnel compensation, evaluations, and other
`
`employment information; information received from a Third Party pursuant to a confidentiality,
`
`non-disclosure or similar agreement; and includes such confidential and proprietary information
`
`about a Third Party, including parents, subsidiaries, and/or other Affiliates. Provisions of this
`
`Protective Order relating to CONFIDENTIAL information shall be understood to encompass any
`
`information derived
`
`from, as well as
`
`testimony and oral conversation related
`
`to,
`
`CONFIDENTIAL information, and all copies, excerpts, and summaries thereof.
`
`3.
`
`“CONFIDENTIAL Discovery Material” means Discovery Material a Producing
`
`Party designates as CONFIDENTIAL pursuant to the terms of this Protective Order, as well as
`
`information provided by a Party pursuant to 42 U.S.C. § 262(l)(1)(B)(i) and 42 U.S.C.
`
`§ 262(l)(2), 42 U.S.C. § 262(l)(3) and 42 U.S.C. § 262(l)(7).
`
`4.
`
`“Designated Inside Counsel” means an Inside Counsel who is designated during
`
`this Litigation pursuant to Paragraph 29(b) of this Protective Order.
`2
`
`
`ME1 30989659v.1
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 3 of 31 PageID #: 1602
`
`
`
`5.
`
`“Discovery Material” means all documents, testimony, pleadings, exhibits, and all
`
`other material or information produced or disclosed in this Litigation, including responses to
`
`requests for production of documents and/or things, answers to interrogatories, responses to
`
`requests for admissions, documents and things made available for inspection, deposition
`
`testimony, expert testimony and reports, and all other discovery taken pursuant to the Federal
`
`Rules of Civil Procedure, including Third Party discovery pursuant to Rule 45, matters in
`
`evidence and any other information hereafter furnished, directly or indirectly, by or on behalf of
`
`any Party, Third Party, or witness in connection with this Litigation. This Protective Order and
`
`protections herein shall apply to all Discovery Material.
`
`6.
`
`“Expert” means a person with specialized knowledge or experience in a matter
`
`pertinent to this Litigation who has been retained by a Party or its Inside or Outside Counsel to
`
`serve as an expert witness or as a consultant in this Litigation who, at the time of retention, is not
`
`an officer, director, or employee of a Party or an Affiliate and is not anticipated to become an
`
`officer, director, or employee of a Party or an Affiliate. Nothing in this Protective Order
`
`purports to alter in any way the requirements for offering testimony under Fed. R. Evid. 703, or
`
`to define the term “expert” for purposes other than those addressed in this Protective Order.
`
`Party.
`
`7.
`
`8.
`
`“Inside Counsel” means any attorney who works in the legal department of a
`
`“Outside Counsel” means any attorney from a law firm that has at least one
`
`attorney who is then a current counsel of record for a Party in this Litigation and which Outside
`
`Counsel is not an employee of a Party or of an Affiliate.
`
`9.
`
`“Party” means a party to this Litigation.
`
`
`ME1 30989659v.1
`
`3
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 4 of 31 PageID #: 1603
`
`
`
`10.
`
`“Patent Office Proceeding” means any proceeding to obtain a patent or to defend
`
`the validity or enforceability of a patent or patent application, including without limitation
`
`prosecution, reexamination, reissue, post-grant review (“PGR”), inter partes review (“IPR”),
`
`inter partes reexaminations, covered business method review proceedings (“CBM”), interference
`
`or any analogous foreign patent proceeding.
`
`11.
`
`“Producing Party” means any Party or any Third Party who produces or otherwise
`
`discloses, whether through formal or informal means, Discovery Material in this Litigation.
`
`12.
`
`“Professional Vendor(s)” means persons or entities that provide litigation support
`
`services (e.g., photocopying, audio or video recording, translating, preparing exhibits or
`
`demonstrations, and organizing, storing, or retrieving data in any form or medium; jury
`
`consulting, mock trial coordination, courtroom presentation) and their employees and
`
`subcontractors.
`
`13.
`
`“Prosecution” means participation in or direct contribution to drafting, amending,
`
`modifying, or advising regarding the drafting, amending, or scope of patent claims during
`
`prosecution proceedings in the United States or in any foreign country. For avoidance of doubt,
`
`(1) Outside Counsel or Designated Inside Counsel who receive CONFIDENTIAL Discovery
`
`Material and who participate in Patent Office Proceedings but do not participate in or advise on
`
`proposing, drafting, or amending claims; and (2) Outside Counsel who do not receive
`
`CONFIDENTIAL Discovery Material shall not be deemed to be engaged in Prosecution and are
`
`not subject to the restrictions regarding Prosecution Bar Patents and Applications set forth
`
`herein.
`
`14.
`
`“Prosecution Bar Patent or Application” means any patent or application (a) to
`
`which any of the patents-in-suit assert priority, or which asserts priority to any of the patents-in-
`
`
`ME1 30989659v.1
`
`4
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 5 of 31 PageID #: 1604
`
`
`
`suit, or which asserts priority to an application or patent to which any of the patents-in-suit assert
`
`priority; (b) is a foreign counterpart of any patent or application defined in (a); (c) that concerns
`
`in whole or in part bevacizumab, trastuzumab, or rituximab, including without limitation
`
`developing, making, purifying, manufacturing, formulating, using or administering any product,
`
`formulation or composition that contains bevacizumab, trastuzumab, or rituximab, including
`
`without limitation methods of treating any disease or medical condition; or (d) that concerns in
`
`whole or in part subject matter related to the patents identified on Genentech’s list under 42
`
`U.S.C. § 262(l)(3)(A), including without limitation as supplemented pursuant to 42 U.S.C.
`
`§ 262(l)(7).
`
`15.
`
`16.
`
`“Protective Order” means this Stipulated Protective Order.
`
`“Receiving Party” means any Party that receives information produced or
`
`otherwise disclosed by any Producing Party.
`
`17.
`
`“Related Litigation” means any additional U.S.
`
`litigation or adversarial
`
`proceeding (including without limitation any Patent Office Proceeding), including any appeals,
`
`between any of the Parties that involves the infringement, validity or enforceability of the
`
`patents-in-suit or a Prosecution Bar Patent or Application.
`
`18.
`
`“Third Party” means a person or entity that is not a Party.
`
`DESIGNATION
`
`19.
`
`Any Producing Party may designate Discovery Material as CONFIDENTIAL in
`
`accordance with this Protective Order if such Party in good faith believes that such Discovery
`
`Material contains CONFIDENTIAL information as defined in Paragraph 2.
`
`20.
`
`Discovery Material may, as appropriate, be marked by the Producing Party with
`
`the legend “CONFIDENTIAL” in conjunction with the identity of the Producing Party, or
`
`another suitable legend, and the Producing Party must use reasonable efforts to ensure that such
`5
`
`
`ME1 30989659v.1
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 6 of 31 PageID #: 1605
`
`
`
`legend appears on each page of each document or file as the format permits. In the case of
`
`computer media, the designation shall be placed on the medium and its label and/or cover. In the
`
`case of files produced in native format, the designation shall be included in the accompanying
`
`metadata and/or in the file’s name.
`
`21.
`
`Information revealed by inspection of things and premises under Fed. R. Civ. P.
`
`34, shall be treated as though it were designated CONFIDENTIAL provided that prior to, or at
`
`any time up to, thirty days (as calculated by Fed. R. Civ. P. 6) after the inspection, the Party
`
`permitting inspection specifically identifies in writing which of the Discovery Material that will
`
`be or that was disclosed by the inspection is to be designated as CONFIDENTIAL. There will
`
`be no waiver of confidentiality, or any privilege or immunity, by the inspection of Discovery
`
`Material before it is copied and marked pursuant to this Order. Inspection of Discovery Material
`
`by any Party shall be conducted by persons eligible under Paragraph 29.
`
`22.
`
`Documents and things produced or made available for inspection may be subject
`
`to redaction, in good faith by the Producing Party, of information that is (a) subject to the
`
`attorney-client privilege, to work-product immunity, or any other applicable privilege or
`
`immunity; (b) protected data, including (i) individually identifiable health information, (ii)
`
`information from any jurisdiction outside that United States that pertains to a specific individual
`
`that can be linked to that individual and that reveals race, ethnic origin, sexual orientation,
`
`political opinions, religious or philosophical beliefs, trade union or political party membership or
`
`that concerns an individual’s health, and (iii) sensitive proprietary information concerning
`
`antibodies or small molecules not relevant to the issues in this litigation, that the Producing Party
`
`claims requires protections under the terms of this Order; or (c) information in a license
`
`agreement or settlement agreement concerning U.S. Patent Nos. 6,331,415 or 7,923,221 that
`
`
`ME1 30989659v.1
`
`6
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 7 of 31 PageID #: 1606
`
`
`
`would tend to identify the counterparty to such agreement. Each such redaction, regardless of
`
`size, shall be clearly labeled “Redacted – Privileged,” “Redacted – Protected Data,” or “Redacted
`
`– Settlement Agreement” as appropriate. This Paragraph shall not be construed as a waiver of
`
`any Party’s right to seek disclosure of redacted information.
`
`23.
`
`Information of a Producing Party revealed during a deposition upon oral or
`
`written examination under Fed. R. Civ. P. 30 shall be treated as CONFIDENTIAL by a
`
`Receiving Party for thirty days (as calculated by Fed. R. Civ. P. 6) following receipt of the final
`
`transcript by Outside Counsel for the Producing Party, but not thereafter unless, before the thirty
`
`day period has expired, Outside Counsel or Inside Counsel for the Producing Party notifies
`
`Outside Counsel or Designated Inside Counsel for the Receiving Party in writing that the
`
`Discovery Material set forth in the transcript is CONFIDENTIAL. Counsel for any Party or
`
`Third Party also may designate the transcript or portions thereof to be CONFIDENTIAL
`
`Discovery Material during the deposition. The appropriate legend described in Paragraph 20
`
`shall be placed on the front of any deposition transcript (and, if recorded, any copies of the
`
`recording) containing CONFIDENTIAL Discovery Material.
`
`24.
`
`Any court filing that contains, describes, or discusses CONFIDENTIAL
`
`Discovery Material shall be filed under seal pursuant to the requirements of District of Delaware
`
`Local Rule 5.1.3, the Court’s CM/ECF Procedures, and any other applicable rules or procedures.
`
`The filing Party must include on the cover page of the brief or other filing a descriptive legend in
`
`the following format: “CONTAINS PLAINTIFFS’ CONFIDENTIAL INFORMATION” or
`
`“CONTAINS DEFENDANT’S CONFIDENTIAL
`
`INFORMATION” or “CONTAINS
`
`PLAINTIFFS’ AND DEFENDANT’S CONFIDENTIAL INFORMATION” or “CONTAINS
`
`THIRD-PARTY CONFIDENTIAL INFORMATION” or another suitable legend. The sealed
`
`
`ME1 30989659v.1
`
`7
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 8 of 31 PageID #: 1607
`
`
`
`material shall not be opened or released from the custody of the Clerk of Court except by order
`
`of the Court. Outside Counsel for the Party filing papers containing, describing, or discussing
`
`CONFIDENTIAL Discovery Material shall be responsible for providing appropriately redacted
`
`copies of the filed document to the Court in accordance with any local rules or procedures. If the
`
`filing contains the CONFIDENTIAL Discovery Material of the Party who did not file the
`
`document, within five days (5) from the date of a filing made under seal, Outside Counsel for the
`
`non-filing Party or non-filing Third Party shall deliver to Outside Counsel for the filing Party or
`
`Third Party a proposed public version of the filing that was made under seal if it contains the
`
`non-filing Party’s CONFIDENTIAL Discovery Material, and this proposed public version shall
`
`include redactions of CONFIDENTIAL Discovery Material. Within two (2) days after receipt of
`
`the proposed public version, Outside Counsel for the filing Party shall provide any additional
`
`redactions it believes appropriate. Redacted versions of papers filed under seal may be made
`
`publicly available provided that (a) all CONFIDENTIAL Discovery Material is redacted; and (b)
`
`such redacted versions are clearly marked “Public Version,” and clearly identify each place
`
`where information or exhibits have been redacted or deleted. A Party shall not disclose another
`
`Party’s CONFIDENTIAL Discovery Material in a public hearing or at trial absent either (a)
`
`advance notice to the other Party to enable the Party to seek appropriate relief from the Court in
`
`the form of an order sealing the courtroom or otherwise; or (b) an order of the Court.
`
`USE
`
`25.
`
`CONFIDENTIAL Discovery Material produced by a Party or Third Party may be
`
`used by a Receiving Party only for purposes of this Litigation. CONFIDENTIAL Discovery
`
`Material shall not be used for any other purpose including, but not limited to, any other lawsuit;
`
`Patent Office Proceeding; any dispute resolution proceeding unrelated to this Litigation; any
`
`petitioning, counseling, or litigation or other work involving the Food and Drug Administration
`8
`
`
`ME1 30989659v.1
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 9 of 31 PageID #: 1608
`
`
`
`(“FDA”), including any Citizens’ Petition; or for any other business, proprietary, commercial,
`
`governmental, or regulatory purpose, domestic or foreign. Nothing in this Protective Order
`
`precludes a Producing Party from using or disseminating its own Discovery Material, including
`
`CONFIDENTIAL Discovery Material, for purposes other than this Litigation. Any recipient of
`
`CONFIDENTIAL Discovery Material shall be subject to the specific limitations applying to that
`
`recipient on the disclosure of that CONFIDENTIAL Discovery Material as provided in this
`
`Protective Order.
`
`26.
`
`During the deposition or trial testimony of any fact witness, such witness may be
`
`shown, testify concerning, or be examined concerning CONFIDENTIAL Discovery Material
`
`only if:
`
`(a)
`
`(b)
`
`the witness is a current employee of the Producing Party;
`
`the witness authored the CONFIDENTIAL Discovery Material or the
`
`witness received the CONFIDENTIAL Discovery Material in the ordinary course of business
`
`and outside the context of this Litigation; or
`
`(c)
`
`the witness is a former director, officer, agent and/or employee of a
`
`Producing Party and the examining Party reasonably believes the witness had access to the
`
`CONFIDENTIAL Discovery Material in the course of his or her employment.
`
`27.
`
`At the deposition of any corporate representative designated pursuant to Fed. R.
`
`Civ. P. 30(b)(6) to testify on behalf of a Party on a particular topic or subject area, such witness
`
`may be shown CONFIDENTIAL Discovery Material that is within that particular topic or
`
`subject area if the Producing Party is the party being deposed pursuant to Fed. R. Civ. P.
`
`30(b)(6).
`
`
`ME1 30989659v.1
`
`9
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 10 of 31 PageID #: 1609
`
`
`
`28.
`
`Third Parties may designate as CONFIDENTIAL deposition transcripts of their
`
`witnesses and any Discovery Material they produce, whether voluntarily or by subpoena, to the
`
`same extent and in the same manner as Parties and any such CONFIDENTIAL Discovery
`
`Material shall be treated by the Parties in the same manner as the CONFIDENTIAL Discovery
`
`Material produced by a Party. Third Parties shall have the same rights and obligations under this
`
`Protective Order as Parties and may move the Court to enforce the provisions of this Protective
`
`Order.
`
`DISCLOSURE OF CONFIDENTIAL DISCOVERY MATERIAL
`
`29.
`
`Unless otherwise directed by the Court or authorized in writing by the Producing
`
`Party, CONFIDENTIAL Discovery Material may be disclosed by a Receiving Party only to the
`
`following persons:
`
`(a)
`
`Outside Counsel for Genentech, Inc., City of Hope, or Hoffman-La Roche
`
`in the above-captioned case:
`
`i.
`
`ii.
`
`McCarter & English LLP
`
`Covington & Burling LLP
`
`iii.
`
`Durie Tangri LLP
`
`
`
`Outside Counsel for Pfizer Inc. in the above-captioned case:
`
`i.
`
`ii.
`
`Heyman Enerio Gattuso & Hirzel LLP
`
`Willkie Farr & Gallagher LLP
`
`provided such Outside Counsel has no current responsibility or involvement and will not have
`
`any responsibility or involvement for the duration of this Litigation for or in (a) the Prosecution
`
`of any Prosecution Bar Patent or Application or (b) participating in or advising on proposing,
`
`drafting, or amending claims of any Prosecution Bar Patent or Application in any Patent Office
`
`Proceedings. The restriction described in this Paragraph shall apply only to individuals who
`10
`
`
`ME1 30989659v.1
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 11 of 31 PageID #: 1610
`
`
`
`received CONFIDENTIAL information and only begin when access to CONFIDENTIAL
`
`information is first received by the affected individual and shall end one year after final
`
`termination of this Litigation.
`
`(b)
`
`Up to three Designated Inside Counsel for Plaintiffs collectively, and up to
`
`three Designated Inside Counsel for Defendant, who, because of their duties and responsibilities,
`
`require access to CONFIDENTIAL Discovery Material, provided such Designated Inside
`
`Counsel have no current involvement and will not have involvement for the duration of this
`
`Litigation in (a) the Prosecution of any Prosecution Bar Patent or Application or (b) participating
`
`in or advising on proposing, drafting, or amending claims of any Prosecution Bar Patent in any
`
`Patent Office Proceedings. A Designated Inside Counsel’s role as supervisor of an attorney or
`
`patent agent engaged in Prosecution described herein shall not, in itself constitute evidence that
`
`the Designated Inside Counsel is engaged in Prosecution or participating in or advising on
`
`proposing, drafting, or amending claims of any Prosecution Bar Patent in any Patent Office
`
`Proceedings. The restriction described in this Paragraph shall begin when access to
`
`CONFIDENTIAL information is first received by the affected individual and shall end the
`
`earlier of (i) one year after final termination of this Litigation or (ii) one year after a Designated
`
`Inside Counsel withdraws from representing a Party in this Litigation and the Party that the
`
`Designated Inside Counsel represents removes him or her from its list of Designated Inside
`
`Counsel.
`
`(c)
`
`Support personnel for attorneys listed in Paragraphs 29(a) and (b), such as
`
`law clerks, paralegals, secretaries, IT personnel, and clerical staff, assisting with this Litigation
`
`under the supervision of an attorney described in Paragraph 29(a) and (b).
`
`
`ME1 30989659v.1
`
`11
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 12 of 31 PageID #: 1611
`
`
`
`(d)
`
`Analysts and scientific advisors regularly employed by Outside Counsel
`
`so long as they are subject to the same restrictions set forth in Paragraph 29(a).
`
`(e)
`
`Contract attorneys retained by a Party’s Outside Counsel or Designated
`
`Inside Counsel for the sole purpose of assisting with document review in this Litigation so long
`
`as they are subject to the same restrictions set forth in Paragraph 29(a).
`
`(f)
`
`Any Expert who is expressly retained by any Outside Counsel or
`
`Designated Inside Counsel to assist in this Litigation, including any associates or analysts
`
`working under the supervision of the Expert, with disclosure only to the extent necessary to
`
`perform such work.
`
`(g)
`
`Support personnel for Experts listed in Paragraph 29(f), such as secretaries
`
`and clerical staff, assisting with this Litigation under the supervision of an Expert described in
`
`Paragraph 29(f).
`
`(h)
`
`Any interpreter, court reporter, or other shorthand reporter or typist who is
`
`not employed by a Party and who is translating, recording, or transcribing documents or
`
`testimony in connection with this Litigation, and any videographer who is not employed by a
`
`Party and who is recording a deposition in connection with this Litigation.
`
`(i)
`
`(j)
`
`(k)
`
`Professional Vendors, as defined in Paragraph 12.
`
`Personnel of the Court and all appropriate courts of appellate jurisdiction.
`
`Any other person requested by a Receiving Party and agreed to by the
`
`Producing Party in writing pursuant to Paragraph 31.
`
`30.
`
`CONFIDENTIAL Discovery Material shall not be disclosed to persons described
`
`in Paragraphs 29(d), (f), or (k), or jury consultants under (i), unless and until such person has
`
`executed an acknowledgement in the form attached as Exhibit A. Either Outside Counsel or
`
`
`ME1 30989659v.1
`
`12
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 13 of 31 PageID #: 1612
`
`
`
`Designated Inside Counsel must maintain a copy of the executed Exhibit A for each individual
`
`falling under Paragraphs 29(d), (f), or (k), and each jury consultant under (i), during the
`
`Litigation and for a period of one year thereafter.
`
`31.
`
`During the pendency of this Litigation, a Party that seeks to disclose
`
`CONFIDENTIAL Discovery Material to an individual described in Paragraph 29(f), or (k) must
`
`first provide notice to the Producing Party by service of a Notice on the other Party identifying
`
`such individual by name and including a curriculum vitae (“CV”) or equivalent resume
`
`disclosing the individual’s employment history, past or present relationship with any of the
`
`Parties and Affiliates, all cases in which the individual has testified in a deposition or a trial in
`
`the past four years, and an executed acknowledgement in the form of Exhibit A attached hereto.
`
`A Party that provides such Notice to the Producing Party may disclose CONFIDENTIAL
`
`Discovery Material to the individual unless, within seven days of delivering the notice (as
`
`calculated by Fed. R. Civ. P. 6), the Party receives written objection from the objecting Party.
`
`Any such objection must be made for good cause and must set forth in detail the grounds on
`
`which such objection is based. A Party that receives a timely written objection must meet and
`
`confer with the objecting Party to try to resolve the matter by agreement. If the Parties are
`
`unable to reach agreement regarding such objection, the objecting Party must apply to the Court
`
`for a protective order no later than ten days (as calculated by Fed. R. Civ. P. 6) after receipt of
`
`the executed acknowledgement in the form attached as Exhibit A and the CV or resume. The
`
`burden shall be on the objecting Party to demonstrate to the Court why such individual should
`
`not be permitted to receive CONFIDENTIAL Discovery Material under the Protective Order.
`
`CONFIDENTIAL Discovery Material shall not be disclosed to such individual pending the
`
`
`ME1 30989659v.1
`
`13
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 14 of 31 PageID #: 1613
`
`
`
`Court’s resolution of the dispute. The foregoing seven-day and ten-day periods may be extended
`
`or shortened by agreement of the Parties or by Order of the Court.
`
`32.
`
`CONFIDENTIAL Discovery Material shall not be disclosed to persons described
`
`in Paragraph 29(b) unless and until such person has executed an acknowledgement in the form
`
`attached as Exhibit B. Either Outside Counsel or Designated Inside Counsel must maintain a
`
`copy of the executed Exhibit B for each individual falling under Paragraph 29(b) during the
`
`Litigation and for a period of one year thereafter. During the pendency of this Litigation, a Party
`
`that seeks to designate a Designated Inside Counsel, or designate a replacement Designated
`
`Inside Counsel with a new designee (as provided herein), must first provide notice to the other
`
`Party by service of the acknowledgement in the form attached as Exhibit B completed and signed
`
`by the proposed Designated Inside Counsel. A Party that designates a Designated Inside
`
`Counsel or replaces a Designated Inside Counsel and provides the information specified in the
`
`preceding sentence may disclose CONFIDENTIAL information to the newly identified
`
`Designated Inside Counsel unless, within five days of delivering the notice (as calculated by Fed.
`
`R. Civ. P. 6), the Party receives a written objection from the objecting Party. Any such objection
`
`must set forth in detail the grounds on which such objection is based. A Party that receives a
`
`timely written objection must meet and confer with the objecting Party to try to resolve the
`
`matter by agreement. If the Parties are unable to reach agreement regarding such designation,
`
`the objecting Party must apply to the Court for a protective order no later than ten days (as
`
`calculated by Fed. R. Civ. P. 6) after receipt of the executed acknowledgement in the form
`
`attached as Exhibit B. CONFIDENTIAL Discovery Material shall not be disclosed to such
`
`Designated Inside Counsel or replacement Designated Inside Counsel pending the Court’s
`
`
`ME1 30989659v.1
`
`14
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 15 of 31 PageID #: 1614
`
`
`
`resolution of the dispute. The foregoing five-day and ten-day periods may be extended or
`
`shortened by agreement of the Parties or by Order of the Court.
`
`33.
`
`The recipient of any CONFIDENTIAL Discovery Material that is provided under
`
`this Protective Order (including any copies or excerpts made thereof) shall maintain such
`
`information (including any summaries, analyses, or other derivative materials disclosing or
`
`reflecting the content of that information) in a secure and safe area and shall exercise reasonable
`
`and proper care with respect to the storage, custody, use, and/or dissemination of such
`
`information. The recipient of CONFIDENTIAL Discovery Material in electronic form shall
`
`maintain such CONFIDENTIAL Discovery Material (including any summaries, analyses, or
`
`other derivative materials disclosing or reflecting the content of that material) on a secure,
`
`password-protected computer, drive, or server such that access to CONFIDENTIAL Discovery
`
`Material is restricted only to persons authorized under Paragraph 29.
`
`EXEMPTED MATERIALS AND OBJECTION TO DESIGNATIONS
`
`34.
`
`Any Receiving Party may object to the designation by the Producing Party of any
`
`Discovery Material as CONFIDENTIAL at any time for any reason including but not limited to
`
`that the Discovery Material is improperly designated as Confidential under Paragraph 36. The
`
`process for making an objection to the designation of Discovery Material as CONFIDENTIAL
`
`and for resolving the dispute shall be as follows:
`
`(a)
`
`Outside Counsel or Designated Inside Counsel for a Receiving Party shall
`
`notify Outside Counsel for the Producing Party in writing as to its objection(s) to the
`
`designations. This notice shall include, at a minimum, a specific identification of the designated
`
`CONFIDENTIAL Discovery Material as well as the reasons for the objection.
`
`
`ME1 30989659v.1
`
`15
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 16 of 31 PageID #: 1615
`
`
`
`(b) Within 14 days of such notice, Outside Counsel or Designated Inside
`
`Counsel for the Parties shall confer either in person or by telephone in a good-faith effort to
`
`resolve the dispute.
`
`(c)
`
`If agreement is not reached, a Receiving Party may apply to the Court for
`
`a ruling that the Discovery Material sought to be protected is not entitled to such designation
`
`within 21 days of such notice. The Receiving Party bears the burden to establish that the
`
`Discovery Material is not CONFIDENTIAL as defined in Paragraphs 2 and 3 and not entitled to
`
`such protection under this Protective Order. Absent agreement by the Parties, the Receiving
`
`Party’s failure to contact the court within 21 days of the notice described in this section waives
`
`the Receiving Party’s objections.
`
`35.
`
`The right to challenge and the process for challenging the existence or designation
`
`of redactions shall be the same as the right to challenge and the process for challenging the
`
`designation of CONFIDENTIAL Discovery Material as set forth in Paragraph 36.
`
`36.
`
`Discovery Material is not properly designated as CONFIDENTIAL under
`
`Paragraph 2 if it has/had been:
`
`(a)
`
`(b)
`
`available to the public at the time of its production hereunder;
`
`available to the public after the time of its production through no act, or
`
`failure to act, on behalf of a Receiving Party, its counsel, representatives, or experts;
`
`(c)
`
`known to a Receiving Party, or shown to have been independently
`
`developed by a Receiving Party, before its production herein without the use or benefit of
`
`Discovery Material;
`
`(d)
`
`obtained outside of this Litigation by a Receiving Party from the
`
`Producing Party without having been designated as CONFIDENTIAL; provided, however, that
`
`
`ME1 30989659v.1
`
`16
`
`

`

`Case 1:19-cv-00638-CFC Document 26 Filed 07/19/19 Page 17 of 31 PageID #: 1616
`
`
`
`this provision does not negate a protective order in another action or any other pre-existing
`
`obligation of confidentiality;
`
`(e)
`
`previously produced, disclosed, and/or provided by the Producing Party to
`
`a Receiving Party or any Third Party without an obligation of confidentiality; or
`
`(f)
`
`obtained by a Receiving Party from a Third Party provided the production
`
`by the Third Party did not violate this Protective Order or a protective order in another action.
`
`37.
`
`Notwithstanding any challenge to the designation of Discovery Material as
`
`CONFIDENTIAL, including according to the provisions of Paragraphs 36(a)–36(f), all such
`
`material so designated shall be treated as such and shall be subject to the provisions of this
`
`Protective Order until one of the following occurs: (a) the Party that designated the material as
`
`CONFIDENTIAL withdraws such designa